BTG plc’s Sell Rating Reaffirmed at FinnCap (BTG)
BTG plc (LON:BTG)‘s stock had its “sell” rating reissued by stock analysts at FinnCap in a report issued on Thursday. They currently have a GBX 345 ($5.71) target price on the stock. FinnCap’s price objective points to a potential downside of 46.51% from the stock’s previous close.
BTG has been the subject of a number of other recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of BTG plc in a research note on Tuesday. Finally, analysts at Jefferies Group upgraded shares of BTG plc to a “buy” rating in a research note on Tuesday, July 29th. They now have a GBX 760 ($12.58) price target on the stock, up previously from GBX 525 ($8.69). Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of GBX 553.57 ($9.16).
BTG plc (LON:BTG) traded down 2.42% on Thursday, hitting GBX 645.00. The stock had a trading volume of 232,691 shares. BTG plc has a 52 week low of GBX 363.00 and a 52 week high of GBX 665.00. The stock has a 50-day moving average of GBX 616.0 and a 200-day moving average of GBX 586.8. The company’s market cap is £2.328 billion.
BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with Analyst Ratings Network's FREE daily email newsletter.